Kolwelter, Julie
Kannenkeril, Dennis
Linz, Peter
Jung, Susanne
Nagel, Armin M.
Bosch, Agnes
Ott, Christian
Bramlage, Peter
Nöh, Lisa
Schiffer, Mario
Uder, Michael
Achenbach, Stephan
Schmieder, Roland E.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure
https://doi.org/10.1186/s12933-021-01410-7
The SGLT2 inhibitor empagliflozin reduces tissue sodium content in patients with chronic heart failure: results from a placebo-controlled randomised trial
https://doi.org/10.1007/s00392-022-02119-7
Funding for this research was provided by:
Boehringer Ingelheim
Universitätsklinikum Erlangen
Article History
Received: 3 September 2022
Accepted: 17 October 2022
First Online: 26 October 2022
Declarations
:
: RES received speaker fees and advisory board fees and PB has received research funding (related and unrelated to the present work) from Boehringer Ingelheim Pharma GmbH & Co. KG during the conduct of the trial. All other authors declare that there is no conflict of interest.
: The trial was approved by the Ethics Committee of the University of Erlangen. The trial was performed in accordance with the principles of the Declaration of Helsinki. All patients provided written informed consent prior to inclusion in the trial. The trial was registered at ExternalRef removed (NCT03128528).